Clinical Trial Update: Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation [Phase 2]

View source ↗

Summary

Phase 2 pilot trial evaluating Reparixin to prevent early allograft dysfunction after liver transplantation; the study was terminated but results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allograft Dysfunction
• Ischemia-reperfusion Injury in Liver Transplant

Drugs mentioned

• Reparixin (reparixin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Ischemia-reperfusion Injury in Liver Transplant, Early Allograft Dysfunction | Phase 2 | Status: TERMINATED | Results posted: 2024-12-11